Wed, September 1, 2021
Tue, August 31, 2021
Mon, August 30, 2021
Fri, August 27, 2021
Thu, August 26, 2021
Wed, August 25, 2021
Tue, August 24, 2021
Mon, August 23, 2021
Fri, August 20, 2021
Thu, August 19, 2021
Wed, August 18, 2021

Vikram Purohit Downgraded (TBPH) to Sell and Decreased Target to $14 on, Aug 25th, 2021


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. and-decreased-target-to-14-on-aug-25th-2021.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Vikram Purohit of Morgan Stanley, Downgraded "Theravance Biopharma, Inc." (TBPH) to Sell and Decreased Target from $27 to $14 on, Aug 25th, 2021.

Vikram has made no other calls on TBPH in the last 4 months.



There are 4 other peers that have a rating on TBPH. Out of the 4 peers that are also analyzing TBPH, 1 agrees with Vikram's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Marc Frahm of "Cowen & Co." Downgraded from Buy to Hold and Decreased Target to $14 on, Tuesday, August 24th, 2021


These are the ratings of the 3 analyists that currently disagree with Vikram


  • Douglas Tsao of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $21 on, Tuesday, August 24th, 2021
  • Geoffrey Porges of "SVB Leerink" Maintained at Buy with Decreased Target to $29 on, Tuesday, August 24th, 2021
  • Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $18 on, Tuesday, August 24th, 2021

Publication Contributing Sources